Instylla, Inc., a Bedford, MA-based company developing next-generation liquid embolics for peripheral vascular embolotherapy, closed a $30m financing round.
This round was led by new investor Delos Capital, with continued participation from the investor syndicate of Excelestar Ventures, Ascension Ventures, Catalyst Health Ventures, Amed Ventures, Sparta Group, and Incept, LLC. As part of this round of financing, Henry Chen, Managing Partner, Delos Capital has joined the Instylla Board of Directors.
The company intends to use the funds for the ongoing prospective clinical trials and early commercialization.
Led by Amar Sawhney, CEO, Instylla is focused on developing next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis. The company’s first product, Embrace HES, is designed for controlled, complete, and persistent embolization in these clinical conditions.
The Instylla HES Hypervascular Tumor Pivotal Study is currently enrolling patients in the US and Canadato evaluate the safety and effectiveness of the Instylla Hydrogel Embolic System (HES) compared with standard of care transcatheter arterial embolization or transcatheter arterial chemoembolization for the vascular occlusion of hypervascular tumors. The “HALT” Study was recently launched in the US and is continuing to enroll patients to study the safety and effectiveness of Embrace HES for the embolization of arterial bleeding in solid organs and peripheral arteries.
Instylla was founded in 2017 by Incept LLC.
FinSMEs
16/08/2023